An interventional study of phacoemulsification with implantation of presbyopia correcting IOL in Loss of Visual Contrast Sensitivity, Near Vision and Visual Impairment, sponsored by Dar Al Shifa Hospital. Completed at 1 site in Kuwait. Per ClinicalTrials.gov, last updated 2021-06-01.
Sponsored by Dar Al Shifa Hospital · Not applicable, Interventional, and Treatment
The purpose of the current study was to compare the visual performance after bilateral implantation of the Panoptix IOL , or the AT LISA IOL or Tecnis Symfony IOL . The focus was on intermediate vision, defocus curves, and contrast sensitivity.
1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.
This study's enrollment of 50 is below the median of 78 across 923 interventional studies indexed under Myopia.
Browse Myopia studies →Dar Al Shifa Hospital is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
panoptix PANFOCAL intraocular lensis a single-piece aspheric non-apodized diffractive panfocal IOL that distributes light energy to three focal points in both small and large pupil conditions
Procedure: phacoemulsification with implantation of presbyopia correcting IOL
Trifocal Diffractive the AT LISA is a preloaded single-piece aspheric diffractive trifocal IOL and made of hydrophilic acrylic with a hydrophobic surface with an ultraviolet absorber. This aspheric IOL is aberration -correcting in order to reduce and compensate for corneal spherical aberrations.
Procedure: phacoemulsification with implantation of presbyopia correcting IOL
SYMPHONY EDOF intraocular lens is a single-piece aspheric biconvex hydrophobic acrylic IOL with a 6.0 mm optic and an 13.0 mm overall diameter. This IOL consists of a wavefront-designed anterior aspheric surface (negative spherical aberration of -0.27 mm to counterbalance the net positive spherical aberration from cornea) and a posterior achromatic diffractive surface with echelette design.
Procedure: phacoemulsification with implantation of presbyopia correcting IOL
cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
visual acuity
The monocular uncorrected (UDVA) and corrected (CDVA) distance visual acuity (4 m), uncorrected intermediate visual acuity (UIVA) (60 cm and 80 cm), distance-corrected intermediate visual acuity (DCIVA), uncorrected near visual acuity (40 cm), and distance-corrected near visual acuity (DCNVA) were assessed. Standardized logarithm of the minimum angle of resolution (logMAR) charts were used for visual acuity measurement at 4 m, 80 cm, and 40 cm.
Time frame: 6 months postoperatively.
defocus curve
The binocular defocus curve was done to evaluate the functional range of vision. The curve was obtained while the patient wearing his distance correction to provide the best distance visual acuity in both eyes. The test was performed under photopic conditions (85 candelas/m2) using ETDRS charts at a distance of 4m with the introduction of defocusing lenses from +1.00 D to -4.00 D in 0.50 D steps.
Time frame: 6 months postoperatively.
contract senstivity
The CSV-1000 system (Vector Vision Inc. Greenville, OH, USA) was used to measure contrast sensitivity under photopic and mesopic conditions without glare with spatial frequencies ranging between 3 and 18 cycles/degree.
Time frame: 6 months postoperatively.
photic phenomena
The presence of dysphotopsia including haloes, glare and starburst were assessed regarding their frequency, severity and the degree of bother.
Time frame: 6 months postoperatively.
spectacle independence
patients were given a questionnaire to assess their spectacle independence. The response for spectacle independence was yes or no.
Time frame: 6 months postoperatively.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dar Al Shifa Hospital